Jounce Therapeutics Inc
F:21J
Income Statement
Earnings Waterfall
Jounce Therapeutics Inc
Income Statement
Jounce Therapeutics Inc
| Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
17
N/A
|
37
+120%
|
58
+55%
|
78
+35%
|
79
+2%
|
72
-9%
|
63
-13%
|
62
-1%
|
58
-6%
|
65
+12%
|
65
0%
|
63
-3%
|
168
+167%
|
148
-12%
|
137
-7%
|
119
-13%
|
0
N/A
|
62
N/A
|
64
+2%
|
89
+40%
|
89
N/A
|
27
-70%
|
25
-6%
|
0
N/A
|
0
N/A
|
82
N/A
|
|
| Operating Income | ||||||||||||||||||||||||||||||
| Operating Expenses |
(19)
|
(30)
|
(42)
|
(47)
|
(52)
|
(61)
|
(72)
|
(82)
|
(91)
|
(95)
|
(97)
|
(98)
|
(97)
|
(96)
|
(97)
|
(95)
|
(95)
|
(98)
|
(101)
|
(104)
|
(107)
|
(108)
|
(110)
|
(115)
|
(118)
|
(127)
|
(132)
|
(133)
|
(134)
|
|
| Selling, General & Administrative |
(5)
|
(8)
|
(14)
|
(15)
|
(17)
|
(20)
|
(20)
|
(22)
|
(23)
|
(24)
|
(25)
|
(26)
|
(26)
|
(27)
|
(28)
|
(28)
|
(28)
|
(28)
|
(28)
|
(29)
|
(29)
|
(29)
|
(29)
|
(29)
|
(29)
|
(29)
|
(29)
|
(30)
|
(31)
|
|
| Research & Development |
(14)
|
(22)
|
(28)
|
(32)
|
(35)
|
(42)
|
(52)
|
(60)
|
(68)
|
(71)
|
(72)
|
(72)
|
(70)
|
(69)
|
(69)
|
(67)
|
(67)
|
(69)
|
(72)
|
(75)
|
(79)
|
(80)
|
(81)
|
(86)
|
(89)
|
(99)
|
(103)
|
(103)
|
(103)
|
|
| Operating Income |
(19)
N/A
|
(30)
-58%
|
(42)
-42%
|
(30)
+30%
|
(15)
+51%
|
(4)
+74%
|
6
N/A
|
(3)
N/A
|
(19)
-638%
|
(33)
-71%
|
(35)
-8%
|
(40)
-12%
|
(31)
+21%
|
(31)
+1%
|
(33)
-8%
|
73
N/A
|
53
-28%
|
39
-26%
|
19
-52%
|
(104)
N/A
|
(45)
+57%
|
(45)
+1%
|
(20)
+54%
|
(25)
-25%
|
(91)
-259%
|
(102)
-12%
|
(132)
-29%
|
(133)
-1%
|
(52)
+61%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||
| Total Other Income |
0
|
0
|
0
|
0
|
1
|
1
|
2
|
3
|
3
|
3
|
3
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
3
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Pre-Tax Income |
(19)
N/A
|
(30)
-58%
|
(42)
-42%
|
(29)
+30%
|
(14)
+53%
|
(2)
+83%
|
8
N/A
|
(0)
N/A
|
(16)
-16 300%
|
(30)
-82%
|
(32)
-8%
|
(36)
-12%
|
(27)
+24%
|
(27)
+2%
|
(29)
-9%
|
78
N/A
|
57
-27%
|
43
-25%
|
22
-49%
|
(102)
N/A
|
(44)
+57%
|
(44)
0%
|
(20)
+55%
|
(25)
-26%
|
(91)
-262%
|
(102)
-12%
|
(131)
-29%
|
(132)
-1%
|
(51)
+62%
|
|
| Net Income | ||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(2)
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(19)
|
(30)
|
(42)
|
(29)
|
(14)
|
(2)
|
7
|
(2)
|
(17)
|
(30)
|
(31)
|
(35)
|
(27)
|
(27)
|
(29)
|
78
|
57
|
43
|
22
|
(102)
|
(44)
|
(44)
|
(20)
|
(25)
|
(91)
|
(102)
|
(131)
|
(132)
|
(51)
|
|
| Net Income (Common) |
(23)
N/A
|
(36)
-57%
|
(50)
-40%
|
(39)
+21%
|
(25)
+38%
|
(12)
+51%
|
(1)
+92%
|
(5)
-420%
|
(17)
-233%
|
(30)
-73%
|
(31)
-4%
|
(35)
-11%
|
(27)
+21%
|
(27)
+2%
|
(29)
-9%
|
78
N/A
|
57
-27%
|
43
-25%
|
22
-49%
|
(102)
N/A
|
(44)
+57%
|
(44)
0%
|
(20)
+55%
|
(25)
-26%
|
(91)
-262%
|
(102)
-12%
|
(131)
-29%
|
(132)
-1%
|
(51)
+61%
|
|
| EPS (Diluted) |
-0.73
N/A
|
-18.78
-2 473%
|
-0.82
+96%
|
-1.26
-54%
|
-0.69
+45%
|
-0.51
+26%
|
-0.05
+90%
|
-0.18
-260%
|
-0.55
-206%
|
-0.93
-69%
|
-0.96
-3%
|
-1.06
-10%
|
-0.83
+22%
|
-0.81
+2%
|
-0.88
-9%
|
2.27
N/A
|
1.7
-25%
|
1.25
-26%
|
0.62
-50%
|
-2.98
N/A
|
-1.1
+63%
|
-0.95
+14%
|
-0.38
+60%
|
-0.49
-29%
|
-1.77
-261%
|
-1.98
-12%
|
-2.55
-29%
|
-2.56
0%
|
-0.99
+61%
|
|